

## AGENDA

DHS IRB Meeting, October 13, 2004, Room 210, 9 a.m.

### PROTOCOLS FOR REVIEW

- **Michael Stevens, M.D.**, Valley Mental Health (VMH), study titled F1D-US-HGLF: Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia, DHS IRB # 030226, **Change Request, Revision 4**, DHS affiliated agency is DSAMH. **RISK LEVEL:** ☐ < Minimal risk; ☐ Minimal Risk; ☒ > Minimal risk but with direct benefit to subjects; ☐ > Minimal risk but no direct benefit to subjects.
- **Michael Stevens, M.D.**, Valley Mental Health (VMH), A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo as ADD-ON Therapy in Schizophrenia, DHS IRB # 030236, **Change Request**, DHS affiliated agency is DSAMH. **RISK LEVEL:** ☐ < Minimal risk; ☐ Minimal Risk; ☒ > Minimal risk but with direct benefit to subjects; ☐ > Minimal risk but no direct benefit to subjects.
- **Catherine Carter, Ph.D.**, VMH, Evaluation of Cognitive and Behavioral Treatment of Compulsive Hoarding, DHS IRB # 040269, DHS affiliated agency is the Division of Substance Abuse and Mental Health (DSAMH) and with input and concurrence, if necessary, from the Division of Aging and Adult Services (DAAS), **RISK LEVEL:** ☐ < Minimal risk; ☐ Minimal Risk; ☐ > Minimal risk but with direct benefit to subjects; ☐ > Minimal risk but no direct benefit to subjects.